Senores Pharmaceuticals Limited has successfully completed the acquisition of 56,63,804 equity shares, representing 75% of the total paid-up equity share capital, of Apnar Pharma Private Limited. The total consideration for this tranche of acquisition was ₹11,45,78,755 (Eleven Crore Forty-Five Lakh Seventy-Eight Thousand Seven Hundred and Fifty-Five Only). This transaction, which marks the completion of the first tranche as per the Share Purchase Agreement (SPA), was finalized on January 16, 2026. The company had previously intimated its intention to acquire 100% of Apnar Pharma Private Limited on December 15, 2025. The acquisition of the remaining 25% equity shares is anticipated to be completed by the second quarter of Fiscal Year 2027, as previously communicated. All other details outlined in the December 15, 2025 letter remain unchanged.
